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1. Introduction
In modern hepatology, diseases of the biliary epithelium, currently termed cholangiopathies,
represent one of the main gaps in knowledge, both on experimental and clinical grounds, though they
started to draw attention since the late 80s [1]. Cholangiopathies comprise a large group of chronic liver
disorders of many different etiologies, from genetic to immune-mediated (including the most common
primary biliary cholangitis and primary sclerosing cholangitis), drug-induced, infectious, and ischemic,
where the primary target of the damaging agent is the biliary epithelial cell, lining either the intra- or
extrahepatic ducts [1,2]. Often thought as epidemiologically rare, cholangiopathies are instead relevant
as a group, being the main indication of liver transplantation in the pediatric age (nearly 80%) and of a
significant proportion of liver transplants in young adults (up to 20%) [1,2]. Clinically, cholangiopathies
are characterized by a slowly evolving course, essentially marked by cholestasis; however, being largely
asymptomatic, they remain difficult to detect for many years [1,2]. Notwithstanding, cholangiopathies
may progress upon the effects of complex repair mechanisms relying on the cholangiocyte ability
after injury to generate a multitude of signals gathering inflammatory, immune, and stromal cells
into a highly reactive milieu [3]. Thus, in a translational perspective, cholangiopathies have become
a model to understand liver repair and regeneration, and to delve into the pro-oncogenic potential
of chronic inflammation. In this respect, the progression of primary sclerosing cholangitis (PSC)
to cholangiocarcinoma (CCA) has been paradigmatic of this sequence. The aim of this book is to
highlight some recent concepts on the variety of cell interactions, which, in cholangiopathies, are
critical to sustain liver repair and regeneration, inflammation, and malignancy, and how they can
provide diagnostic tools for the early assessment of cholestasis.
2. Cell Interactions in Liver Repair and Regeneration
Activation of the hepatic progenitor cell (HPC) compartment is a functional hallmark of ongoing
liver injury, that, conversely from rodents, in humans, is triggered also by mild forms of damage. HPC
are immature bipotent cells able to differentiate into both the biliary (through generation of ductular
reactive cells) and hepatocyte (via intermediate hepatobiliary cells) lineages [3]. HPC are located in
two specialized anatomical and functional niches—one is parenchymal, abutting the canals of Hering
(HpSC), while the other is ductal, along the biliary tree (BTSC)—within the peribiliary glands (PBG) of
the large intrahepatic and extrahepatic bile ducts. This topic is reviewed by Overi and colleagues [4],
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who describe the different engagement of the two compartments in human conditions, along with the
niche cell composition and the specific signaling pathways underpinning their activation. Interestingly,
HpSC activation and epithelial differentiation is finely regulated by the balance between Notch and Wnt
ligands released by neighboring cells, such as portal myofibroblasts and macrophages. While HpSC
activation is relevant in cholangiopathies associated with extensive fibrosis and disease progression,
BTSCs are prominently involved in PSC upon the effect of Hedgehog ligands produced by the stromal
cells localized nearby the PBGs and their degree of stimulation correlates with the progression of
inflammation through dysplasia and cancer.
The role of PBGs as the cellular origin of CCA has been discussed by Nakagawa and colleagues [5],
underlining their importance in inflammation-induced CCA (i.e., liver fluke infections) and in the
intraductal papillary neoplasms of the bile duct. In this disease context, interleukin (IL)-33 (also known
as “alarmin”) released by inflamed/damaged cholangiocytes behaves as a key mediator by inducing a
potent type 2 innate lymphoid cell (ILC2) response, which in turn secretes IL-13 and amphiregulin,
promoting cholangiocarcinogenesis from PBGs. IL-33 also stimulate a strong proliferative cascade
mediated by IL-6/STAT3 signaling, a signature of the inflammation-associated cholangiocarcinogenesis.
Interestingly, the IL-33-induced proliferative response was observed in cholangiocytes lining the
extrahepatic but not the small intrahepatic bile ducts.
In addition to Notch, Wnt, and Hedgehog, yes-associated protein (YAP) is a morphogen
instrumental for liver regeneration following cholestatic damage. In a mouse model of ductopenia
induced by liver-specific deletion of the central downstream effector of Notch signaling, the
recombination signal binding protein for immunoglobulin kappa j region (RBPJ), Tharehalli and
coworkers found that YAP was activated in response to the increased expression of the scaffolding
protein IQGAP1 induced by bile acid accumulation and stimulated a compensatory hepatocyte
transdifferentiation towards the biliary lineage (intermediate hepatobiliary cells) with upregulation of
the cholangiocyte marker SOX9 [6].
3. Cell Interactions in Inflammatory Cholangiopathies
Besides being the target of damaging insults of diverse etiologies, the cholangiocytes themselves
may behave as initiators and propagators of the inflammatory and immune reactions [1–3]. This
concept is well-exemplified in inflammatory cholangiopathies, where cholangiocytes undergo a
range of phenotypic “neuroendocrine-like” changes enabling them to orchestrate the complex
cellular and molecular interactions occurring in response to damage. Giordano and colleagues [7]
addressed the pathophysiological role of gut-derived bacterial components or metabolites (including
pathogen-associated molecular patterns, PAMPs) delivered to the hepatic parenchyma via the
enterohepatic circulation in sustaining this “reactive” epithelial adaptation to injury of cholangiocytes.
In this landscape, the authors emphasized the “leaky-gut” hypothesis, which has gained strong
consideration in PSC based on the close association with inflammatory bowel diseases (IBD), mainly
ulcerative colitis. However, the authors underlined how, in other conditions, as in the cystic fibrosis
transmembrane conductance regulator (CFTR)-defective cholangiopathy, bacterial products (LPS)
stimulate intense cholangiocyte secretion of pro-inflammatory cytokines via upregulation of TLR4
and the nuclear factor kappa-light-chain-enhancer of the activated B cells (NF-κB) pathway [8].
The intricate scenario of gut microbiota composition has been unraveled by several recent studies
based on high-throughput technologies, in an attempt to define specific signatures in inflammatory
cholangiopathies. Noteworthily, PSC patients seem to present a distinct microbiota profiling with
enrichment in the Enterococcus faecalis species, regardless of its association with IBD [7].
The pro-oncogenic potential of a chronic fibroinflammatory microenvironment and the multiple
molecular players regulating the reciprocal cell interactions have been reviewed by Cannito et al. [9].
The authors focused on two chronic cholangiopathies, namely PSC and congenital hepatic
fibrosis/Caroli’s disease, heralding CCA. Experimental studies in both cholangiopathies have been
favored by the availability of rodent models faithfully recapitulating the phenotype of biliary lesions.
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PSC progression to CCA has been linked to genetic mutations affecting p53 and KRAS signaling, as well
as to nitric oxide production by the inflamed bile ducts. In a mouse model of congenital hepatic fibrosis,
cholangiocytes harbored a perturbation of the β-catenin pathway regulating a low-grade inflammatory
response mainly dominated by macrophages. However, further efforts will be needed to develop models
reproducing the sequential steps underpinning cholangiocarcinogenesis in these cholangiopathies.
An important mediator of the abundant secretory functions enabling cholangiocytes to interact
with other cell types is calcium (Ca2+) signaling. Rodrigues and colleagues [10] reviewed experimental
models to study Ca2+ signaling in cholangiocytes and the Ca2+-dependent mechanisms regulating
cholangiocyte secretory activity. The authors underline the role played by the inositol 1,4,5-triphosphate
receptor (ITPR), the only intracellular Ca2+ release channel expressed by cholangiocytes, which is
transcriptionally regulated by NF-κB and nuclear factor, erythroid 2-like 2 (NRF2), and activated by
pro-inflammatory cytokines and oxidative stress. Importantly, impairment of Ca2+ signaling due to
ITPR loss has been reported in a variety of cholangiopathies, including PSC, primary biliary cholangitis,
and biliary atresia, and is responsible for ductular cholestasis. Thus, stimulation of Ca2+ may represent
a useful strategy for the treatment of cholestatic conditions.
4. Cell Interactions in Malignant Cholangiopathies
Cancer cells are embedded into a complex microenvironment, an “ecosystem” that constitutes an
integral part of the “malignoma” and provides a multitude of factors to the growing tumor. The role of
the stromal compartment and cell–cell interactions for the development of biliary malignancies has
come into focus over the last years. In this highly desmoplastic type of cancer associated, activated
stromal fibroblasts (CAF) often constitute the largest cell population, by far exceeding the number
of actual cancer cells [11]. The clinical importance of CAF is supported by studies that show a
negative correlation of CAF abundance and patient survival [12]. CAFs have been shown to alter
and provide extracellular matrix components such as tenascin C and periostin, thereby facilitating
cancer cell survival and migration. Moreover, they secrete growth factors such as platelet-derived
growth factor (PDGF) that further support tumor growth and metastasis [13]. Therapeutically targeting
this genetically homogeneous cell population is a novel concept [14], yet the cell interactions that
contribute to biliary malignancy development and growth are far more complex as further cell types
importantly contribute to the crosstalk. As Gentilini and colleagues describe comprehensively in
their article [15], several subsets of immune cells are of importance for the process of malignant
transformation. Probably in part attracted by activated CAF, an abundance of tumor-associated
macrophages (TAMs) as well as reduced numbers of specific T-cell subpopulations have also been
negatively correlated with patient survival. TAMs, a specific subset of alternatively activated so-called
M2 macrophages, can promote cancer development by a number of mechanisms from growth factor
secretion to matrix remodeling by metalloproteinases. Besides TAM, tumor infiltrating lymphocytes
as well as NK cells may represent druggable targets in the microenvironment. While the stromal
cells can be considered relatively genetically stable, the biliary cancer cells are characterized by an
array of characteristic genetic aberrations. In their paper, Winkelmann et al. focus on the occurrence
of microsatellite instability (MSI) in cholangiocarcinoma [16]. MSI has earlier been shown to be
a favorable marker for therapy response, particularly to immune-modulatory treatments such as
checkpoint inhibitors (CPI). As the authors demonstrate in a German cohort of CCA patients, MSI is a
rare event in CCA, an important factor to consider when considering clinical trials of, e.g., CPI in CCA.
5. Cell Interactions Provide Tools for the Early Detection of Cholestasis in Cholangiopathies
Cholestasis is a fundamental feature of cholangiopathies, sustained by a complex interplay of
several cell types contributing to biliary damage. Investigations to identify key biomarkers of the
molecular mechanisms involved are sorely needed. As aforementioned, enterohepatic circulation,
resulting in a bidirectional exchange of bioactive compounds, including endogenous (bile components)
and exogenous metabolites (nutrients, xenobiotics, and gut bacteria) between the gut and the liver, is
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a central pathogenetic mechanism of the initiation and progression of cholestasis in several biliary
disorders, particularly in PSC. By performing global metabolomic and lipidomic analysis in the portal
serum and bile of patients with PSC, compared with noncholestatic chronic liver diseases, and of healthy
controls, Tietz-Bogert and Kim et al. found that the bile in PSC had a unique and more homogeneous
profile, enriched in dipeptides and polyamine metabolites, which can alter liver cell homeostasis as
well as the intestinal microbiota [17]. Interestingly, polyamine catabolism has been associated with
intense generation of reactive oxygen species, which represent an important determinant of disease
progression in PSC.
Using real-time spectroscopic autofluorescence analysis of serum and liver tissue in experimental
cholestasis (rats undergoing bile duct ligation), Croce and colleagues observed distinctive changes in
some endogenous fluorophores. In serum, they found a significant increase in porphyrin derivatives,
indicating perturbation of the heme metabolism, while in liver tissue, they described dramatic
changes in the content of NAD(P)H, flavins, and lipofuscin-like lipopigments, reflecting mitochondrial
dysfunction, oxidative stress, and accumulation of oxidized species [18]. Altogether, these molecular
alterations may be regarded as chemical footprints of the initial events occurring in cholestasis, possibly
to take advantage of for early diagnosis.
Oxidative stress is a main pathomechanism of reperfusion injury and biliary complications
following liver transplantation. Cholangiocytes are indeed very sensitive to ischemic damage, leading
to compensatory hyperplastic repair which mainly affects the large extrahepatic bile ducts, whereby it
leads to biliary structuring. Schlegel and Dutkowski provided an overview on this topic, highlighting
the protective effects exerted by machine liver perfusion [19]. In particular, the authors described how
hypothermic oxygenated perfusion (HOPE) applied through the portal vein, eventually combines with
the hepatic artery and protects cholangiocytes from ischemic injury, leading to a significant reduction
in the posttransplant development of biliary strictures.
6. Conclusions
In conclusion, the papers compiled in this special issue underline the importance of different cell
populations and their interaction in the development of biliary diseases. Much insight has been gained
over the last few years in the different disease areas. Still, further in depth understanding and modelling
of the cellular interactions is needed to move forward with the identification of druggable targets and
for clinical trials that will hopefully soon benefit our patients suffering from hepatobiliary conditions.
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